Search

Your search keyword '"Lorentino F"' showing total 110 results
Start Over Author "Lorentino F"
110 results on '"Lorentino F"'

2. Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation

Author

Lorentino, F, Sacchi, N, Oldani, E, Miotti, V, Picardi, A, Gallina, Am, Crivello, P, Bernasconi, P, Saccardi, R, Farina, L, Benedetti, F, Cerno, M, Grassi, A, Bruno, B, Patriarca, F, Ciceri, F, Fleischhauer, K, Vago, L, Bonifazi, F, Lorentino, F., Sacchi, N., Oldani, E., Miotti, V., Picardi, A., Gallina, A. M., Crivello, P., Bernasconi, P., Saccardi, R., Farina, L., Benedetti, F., Cerno, M., Grassi, A., Bruno, B., Patriarca, F., Ciceri, F., Fleischhauer, K., Vago, L., and Bonifazi, F.

Subjects
HLA, Graft-versus-Host-Disease, unrelated donor selection, Medizin, Settore MED/15, Stem Cell Transplantation
Abstract

CA Fleischhauer

Published
2020

9. PS1268 CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM FOR THE TREATMENT OF FEBRILE NEUTROPENIA IN ALLOGENEIC TRANSPLANT RECIPIENTS

Author

Clerici, D., primary, Oltolini, C., additional, Greco, R., additional, Pavesi, F., additional, Giglio, F., additional, Mastaglio, S., additional, Lorentino, F., additional, Lazzari, L., additional, Scarpellini, P., additional, Bernardi, M., additional, Peccatori, J., additional, Corti, C., additional, Castagna, A., additional, and Ciceri, F., additional

Published
2019
Full Text
View/download PDF

10. PF751 POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS IN HAPLOIDENTICAL TRANSPLANT WITH PBSC GRAFTS: RESULTS IN 151 PATIENTS

Author

Silani, M., primary, Greco, R., additional, Albanese, S., additional, Lorentino, F., additional, Stanghellini, M.T. Lupo, additional, Giglio, F., additional, Clerici, D., additional, Lazzari, L., additional, Serio, F., additional, Piemontese, S., additional, Marcatti, M., additional, Mastaglio, S., additional, Assanelli, A., additional, Corti, C., additional, Bernardi, M., additional, Peccatori, J., additional, and Ciceri, F., additional

Published
2019
Full Text
View/download PDF

11. PS1061 ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT)

Author

Bernardi, M.S., primary, Carrabba, M.G., additional, Pavesi, F., additional, Lorentino, F., additional, Mastaglio, S., additional, Messina, C., additional, Vago, L., additional, Gentner, B., additional, Milani, R., additional, Liberatore, C., additional, Casirati, G., additional, Sarah, M., additional, Corti, C., additional, Jacopo, P., additional, and Ciceri, F., additional

Published
2019
Full Text
View/download PDF

12. TREOSULFAN-BASED CONDITIONING AND UNMANIPULATED PERIPHERAL BLOOD HAPLOIDENTICAL TRANSPLANTATION (HAPLOSCT) FOR PRIMARY REFRACTORY AND RELAPSED AML: RESULTS IN 63 PATIENTS

Author

Lorentino F, Bernardi M, Carrabba M, Messina C, Forcina A, Sala E, Pavesi F, Vago L, Gentner B, Milani R, Giglio F, Morelli M, Greco R, Corti C, Peccatori J, Ciceri F, Lorentino, F, Bernardi, M, Carrabba, M, Messina, C, Forcina, A, Sala, E, Pavesi, F, Vago, L, Gentner, B, Milani, R, Giglio, F, Morelli, M, Greco, R, Corti, C, Peccatori, J, and Ciceri, F

Published
2016

14. Pentraxin 3 as a Biomarker for Acute GvHD and Fungal Infections in Allogeneic Transplantation: Results of a Prospective Longitudinal Study in 73 Adult Recipients

Author

Greco R, Sala E, Crucitti L, Morelli M, Stanghellini MTL, Vago L, Assanelli A, Giglio F, Carrabba M, Levati G, Lorentino F, Tassara M, Bottazzi B, Leone R, Corti C, Bernardi M, Peccatori J, Mantovani A, Ciceri F, Garlanda C, Greco, R, Sala, E, Crucitti, L, Morelli, M, Stanghellini, Mtl, Vago, L, Assanelli, A, Giglio, F, Carrabba, M, Levati, G, Lorentino, F, Tassara, M, Bottazzi, B, Leone, R, Corti, C, Bernardi, M, Peccatori, J, Mantovani, A, Ciceri, F, and Garlanda, C

Published
2016

15. BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS

Author

Vaccari LC, Barbanti MC, Giglio F, Morelli M, Mannina D, Perini T, Lazzari L, Mastaglio S, Piemontese S, Lorentino F, Forcina A, Assanelli A, Marktel S, Carrabba M, Vago L, Corti C, Bernardi M, Stanghellini MTL, Peccatori J, Ciceri F, Greco R, Vaccari, Lc, Barbanti, Mc, Giglio, F, Morelli, M, Mannina, D, Perini, T, Lazzari, L, Mastaglio, S, Piemontese, S, Lorentino, F, Forcina, A, Assanelli, A, Marktel, S, Carrabba, M, Vago, L, Corti, C, Bernardi, M, Stanghellini, Mtl, Peccatori, J, Ciceri, F, and Greco, R

Published
2016

16. T-cell immune reconstitution predicts the outcome of Human Herpes Virus 6 Infection in 54 Patients after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Greco R, Crucitti L, Noviello M, Racca S, Barbanti MC, Valtolina V, Dvir R, Vago L, Stanghellini MTL, Giglio F, Morelli M, Rolla S, Lorentino F, Orsini A, Forcina A, Assanelli A, Carrabba M, Marktel S, Bernardi M, Corti C, Peccatori J, Bonini C, Clementi M, Ciceri F, Greco, R, Crucitti, L, Noviello, M, Racca, S, Barbanti, Mc, Valtolina, V, Dvir, R, Vago, L, Stanghellini, Mtl, Giglio, F, Morelli, M, Rolla, S, Lorentino, F, Orsini, A, Forcina, A, Assanelli, A, Carrabba, M, Marktel, S, Bernardi, M, Corti, C, Peccatori, J, Bonini, C, Clementi, M, and Ciceri, F

Published
2015

18. Improving the Diagnostic Algorithm for Sepsis: Adjuvant Role of SeptiFast in 491 Consecutive Hematological Patients

Author

Barbanti MC, Greco R, Mancini N, Orsini A, Crucitti L, Forcina A, Lorentino F, Giglio F, Stanghellini MTL, Vago L, Morelli M, Girlanda S, Clerici D, Carrabba M, Marktel S, Assanelli A, Marcatti M, Bernardi M, Corti C, Peccatori J, Clementi M, Ciceri F, Barbanti, Mc, Greco, R, Mancini, N, Orsini, A, Crucitti, L, Forcina, A, Lorentino, F, Giglio, F, Stanghellini, Mtl, Vago, L, Morelli, M, Girlanda, S, Clerici, D, Carrabba, M, Marktel, S, Assanelli, A, Marcatti, M, Bernardi, M, Corti, C, Peccatori, J, Clementi, M, and Ciceri, F

Published
2015

19. Second Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan-based Conditioning Regimen for Acute Leukemia in Relapse

Author

Peccatori J, Crucitti L, Greco R, Stanghellini MTL, Vago L, Cieri N, Giglio F, Morelli M, Assanelli A, Marcatti M, Carrabba M, Marktel S, Perini T, Lorentino F, Girlanda S, Corti C, Bernardi M, Ciceri F, Peccatori, J, Crucitti, L, Greco, R, Stanghellini, Mtl, Vago, L, Cieri, N, Giglio, F, Morelli, M, Assanelli, A, Marcatti, M, Carrabba, M, Marktel, S, Perini, T, Lorentino, F, Girlanda, S, Corti, C, Bernardi, M, and Ciceri, F

Published
2015

20. Post Transplant Cyclophosphamide (PTCy) and Sirolimus for Haploidentical PBSC HSCT: favorable Immune Reconstitution and Low Rates of GvHD in 40 Patients

Author

Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Lorentino F, Stanghellini MTL, Vago L, Freitas T, Marktel S, Bernardi M, Corti C, Bonini C, Ciceri F, Peccatori J, Cieri, N, Greco, R, Crucitti, L, Morelli, M, Giglio, F, Levati, G, Assanelli, A, Lorentino, F, Stanghellini, Mtl, Vago, L, Freitas, T, Marktel, S, Bernardi, M, Corti, C, Bonini, C, Ciceri, F, and Peccatori, J

Published
2015

21. Standardized care of long-term survivors after allogeneic stem cell transplantation: a cross-sectional 1-year evaluation in 249 adults

Author

Lupo-Stanghellini MT, Orsini A, Mastaglio S, Girlanda S, Perini T, Brambilla M, Tassara M, Lorentino F, Piemontese S, Forcina A, Vago L, Pavesi F, Sala E, Malerba A, Marcatti M, Guggiari E, Marktel S, Assanelli A, Carrabba M, Lunghi F, Bernardi M, Peccatori J, Corti C, Ciceri F, Lupo-Stanghellini, Mt, Orsini, A, Mastaglio, S, Girlanda, S, Perini, T, Brambilla, M, Tassara, M, Lorentino, F, Piemontese, S, Forcina, A, Vago, L, Pavesi, F, Sala, E, Malerba, A, Marcatti, M, Guggiari, E, Marktel, S, Assanelli, A, Carrabba, M, Lunghi, F, Bernardi, M, Peccatori, J, Corti, C, and Ciceri, F

Published
2015

22. Human Herpes Virus 6 Encephalitis: a major challenge after Haploidentical Hematopoietic Stem Cell Transplantation

Author

Greco R, Noviello M, Vago L, Stanghellini MTL, Cieri N, Oliveira G, Giglio F, Morelli M, Valtolina V, Barbanti MC, Lorentino F, Crucitti L, Orsini A, Forcina A, Assanelli A, Carrabba M, Marktel S, Bernardi M, Corti C, Peccatori J, Bordignon C, Bonini C, Ciceri F, Greco, R, Noviello, M, Vago, L, Stanghellini, Mtl, Cieri, N, Oliveira, G, Giglio, F, Morelli, M, Valtolina, V, Barbanti, Mc, Lorentino, F, Crucitti, L, Orsini, A, Forcina, A, Assanelli, A, Carrabba, M, Marktel, S, Bernardi, M, Corti, C, Peccatori, J, Bordignon, C, Bonini, C, and Ciceri, F

Published
2015

23. Sirolimus and Post Transplant Cyclophosphamide (PT-Cy) Allow the Use of Haploidentical PBSC Grafts Inducing a Favorable Immune Reconstitution with Low Rates of GvHD: Results in 39 Patients

Author

Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Lorentino F, Stanghellini MTL, Vago L, Freitas T, Marktel S, Bernardi M, Corti C, Bonini C, Ciceri F, Peccatori J, Cieri, N, Greco, R, Crucitti, L, Morelli, M, Giglio, F, Levati, G, Assanelli, A, Lorentino, F, Stanghellini, Mtl, Vago, L, Freitas, T, Marktel, S, Bernardi, M, Corti, C, Bonini, C, Ciceri, F, and Peccatori, J

Published
2014

24. RAPID MOLECULAR DETECTION OF PATHOGENS IN 1941 BLOOD SAMPLES FROM 516 CONSECUTIVE PATIENTS WITH FEBRILE NEUTROPENIA

Author

Greco R, Mancini N, Lorentino F, Crucitti L, Barbanti MC, Forcina A, Orsini A, Vago L, Giglio F, Morelli M, Levati G, Sala E, Clerici D, Stanghellini MTL, Carrabba M, Marktel S, Assanelli A, Marcatti M, Bernardi M, Peccatori J, Corti C, Clementi M, Ciceri F, Greco, R, Mancini, N, Lorentino, F, Crucitti, L, Barbanti, Mc, Forcina, A, Orsini, A, Vago, L, Giglio, F, Morelli, M, Levati, G, Sala, E, Clerici, D, Stanghellini, Mtl, Carrabba, M, Marktel, S, Assanelli, A, Marcatti, M, Bernardi, M, Peccatori, J, Corti, C, Clementi, M, and Ciceri, F

Published
2014

25. Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia

Author

Greco R, Barbanti MC, Mancini N, Crucitti L, Forcina A, Lorentino F, Orsini A, Vago L, Giglio F, Stanghellini MTL, Clerici D, Carrabba MG, Marktel S, Assanelli A, Marcatti M, Bernardi M, Corti C, Peccatori J, Clementi M, Ciceri F, Greco, R, Barbanti, Mc, Mancini, N, Crucitti, L, Forcina, A, Lorentino, F, Orsini, A, Vago, L, Giglio, F, Stanghellini, Mtl, Clerici, D, Carrabba, Mg, Marktel, S, Assanelli, A, Marcatti, M, Bernardi, M, Corti, C, Peccatori, J, Clementi, M, and Ciceri, F

Published
2014

26. ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES: 4GY TBI TO INTENSIFY TREOSULFAN AND FLUDARABINE-BASED CONDITIONING

Author

Giglio F, Brambilla CZ, Lorentino F, Piemontese S, Crucitti L, Greco R, Morelli M, Messina C, Forcina A, Stanghellini MTL, Vago L, Marktel S, Marcatti M, Assanelli A, Corti C, Bernardi M, Bonini C, Ciceri F, Peccatori J, Giglio, F, Brambilla, Cz, Lorentino, F, Piemontese, S, Crucitti, L, Greco, R, Morelli, M, Messina, C, Forcina, A, Stanghellini, Mtl, Vago, L, Marktel, S, Marcatti, M, Assanelli, A, Corti, C, Bernardi, M, Bonini, C, Ciceri, F, and Peccatori, J

Published
2014

27. VORICONAZOLE PROPHYLAXIS OF INVASIVE FUNGAL INFECTION IN HAPLOIDENTICAL ALLOGENIC STEM CELL TRANSPLANTATION

Author

Sarghi S, Lorentino F, Giglio F, Brambilla CZ, Crucitti L, Levati G, Greco R, Messina C, Forcina A, Stanghellini MTL, Vago L, Marktel S, Marcatti M, Assanelli A, Bernardi M, Peccatori J, Corti C, Ciceri F, Sarghi, S, Lorentino, F, Giglio, F, Brambilla, Cz, Crucitti, L, Levati, G, Greco, R, Messina, C, Forcina, A, Stanghellini, Mtl, Vago, L, Marktel, S, Marcatti, M, Assanelli, A, Bernardi, M, Peccatori, J, Corti, C, and Ciceri, F

Published
2014

28. HUMAN HERPES VIRUS 6 AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Author

Greco R, Lorentino F, Crucitti L, Vago L, Stanghellini MTL, Forcina A, Giglio F, Morelli M, Levati G, Orsini A, Carbone MR, Valtolina V, Noviello M, Marktel S, Assanelli A, Carrabba M, Marcatti M, Peccatori J, Bernardi M, Bonini C, Corti C, Ciceri F, Greco, R, Lorentino, F, Crucitti, L, Vago, L, Stanghellini, Mtl, Forcina, A, Giglio, F, Morelli, M, Levati, G, Orsini, A, Carbone, Mr, Valtolina, V, Noviello, M, Marktel, S, Assanelli, A, Carrabba, M, Marcatti, M, Peccatori, J, Bernardi, M, Bonini, C, Corti, C, and Ciceri, F

Published
2014

29. Intensification Of Treosulfan and Fludarabine-Based Conditioning With 4 Gy TBI For Allogeneic Stem Cell Transplantation In Patients With Hematological Malignancies

Author

Giglio F, Brambilla CZ, Lorentino F, Piemontese S, Crucitti L, Levati G, Greco R, Morelli M, Messina C, Forcina A, Stanghellini MTL, Vago L, Marktel S, Marcatti M, Assanelli A, Corti C, Bernardi M, Bonini C, Ciceri F, Peccatori J, Giglio, F, Brambilla, Cz, Lorentino, F, Piemontese, S, Crucitti, L, Levati, G, Greco, R, Morelli, M, Messina, C, Forcina, A, Stanghellini, Mtl, Vago, L, Marktel, S, Marcatti, M, Assanelli, A, Corti, C, Bernardi, M, Bonini, C, Ciceri, F, and Peccatori, J

Published
2013

33. Multiplex PCR-based assay (SeptiFast) for rapid detection of pathogens in febrile neutropenia: results in 273 consecutive patients

Author

Greco R, Clerici D, MANCINI, NICASIO, CLEMENTI, MASSIMO, Lorentino F, Crucitti L, Matteazzi F, Forcina A, Vago L, Stanghellini MTL, Bernardi M, Peccatori J, Assanelli A, Carrabba M, Corti C., CICERI , FABIO, Greco, R, Clerici, D, Mancini, Nicasio, Clementi, Massimo, Lorentino, F, Crucitti, L, Matteazzi, F, Forcina, A, Vago, L, Stanghellini, Mtl, Bernardi, M, Peccatori, J, Assanelli, A, Carrabba, M, Ciceri, Fabio, and Corti, C.

Published
2012

34. Neuromyelitis optica remission after allo-SCT: results in 2 patients and correlation with T- and B-cell biomarkers of tolerance

Author

Greco R, Lupo Stanghellini MT, Carbone MR, Sala E, Lorentino F, Peccatori J, Corti C, Bernardi M, Valtolina V, Moiola L, Rossi P, Radaelli M, Furlan R, COMI, GIANCARLO, BONINI , MARIA CHIARA, CICERI , FABIO, BONDANZA , ATTILIO, Greco, R, Lupo Stanghellini, Mt, Carbone, Mr, Sala, E, Lorentino, F, Peccatori, J, Corti, C, Bernardi, M, Valtolina, V, Moiola, L, Rossi, P, Radaelli, M, Furlan, R, Comi, Giancarlo, Bonini, MARIA CHIARA, Ciceri, Fabio, and Bondanza, Attilio

Published
2011

36. Human Herpes Virus-6 and Clinical Manifestations After Allogeneic Hematopoietic Stem Cell Transplantation

Author

Greco R, Lorentino F, Clerici D, Matteazzi F, Forcina A, Vago L, Malato S, Stanghellini MTL, Carrabba M, Assanelli A, Marcatti M, Bernardi M, Corti C., BORDIGNON, CLAUDIO, CICERI , FABIO, Greco, R, Lorentino, F, Clerici, D, Matteazzi, F, Forcina, A, Vago, L, Malato, S, Stanghellini, Mtl, Carrabba, M, Assanelli, A, Marcatti, M, Bernardi, M, Bordignon, Claudio, Ciceri, Fabio, and Corti, C.

Published
2011

37. Bone marrow morphology and cytogenetics in donors provide additional safety in allogeneic haematopoietic stem cell transplantation: results in 460 healthy candidates

Author

Lupo Stanghellini MT, Gattillo S, Ronchi P, Guggiari E, Fomo B, Sala E, Lorentino F, Malato S, Bruno Ventre M, Piemontese S, Girlanda S, Tassara M, Zino E, Mazzi B, Bellio L, Malabarba L, Corti C, Bernardi M, Peccatori J, Fleischhauer K, Marcatti M, Rossini S., CICERI , FABIO, Lupo Stanghellini, Mt, Gattillo, S, Ronchi, P, Guggiari, E, Fomo, B, Sala, E, Lorentino, F, Malato, S, Bruno Ventre, M, Piemontese, S, Girlanda, S, Tassara, M, Zino, E, Mazzi, B, Bellio, L, Malabarba, L, Corti, C, Bernardi, M, Peccatori, J, Fleischhauer, K, Marcatti, M, Ciceri, Fabio, and Rossini, S.

Published
2010

38. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation

Author

Forcina, A, primary, Baldan, R, additional, Marasco, V, additional, Cichero, P, additional, Bondanza, A, additional, Noviello, M, additional, Piemontese, S, additional, Soliman, C, additional, Greco, R, additional, Lorentino, F, additional, Giglio, F, additional, Messina, C, additional, Carrabba, M, additional, Bernardi, M, additional, Peccatori, J, additional, Moro, M, additional, Biancardi, A, additional, Nizzero, P, additional, Scarpellini, P, additional, Cirillo, D M, additional, Mancini, N, additional, Corti, C, additional, Clementi, M, additional, and Ciceri, F, additional

Published
2016
Full Text
View/download PDF

40. Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): A single center experience

Author

Ciceri⁎, F., primary, Vignati, A., additional, Giglio, F., additional, Tassara, M., additional, Sala, E., additional, Pavesi, F., additional, Lorentino, F., additional, Messina, C., additional, Carrabba, M., additional, Crotta, A., additional, and Bernardi, M., additional

Published
2012
Full Text
View/download PDF

41. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniaein hematopoietic stem cell transplantation

Author

Forcina, A, Baldan, R, Marasco, V, Cichero, P, Bondanza, A, Noviello, M, Piemontese, S, Soliman, C, Greco, R, Lorentino, F, Giglio, F, Messina, C, Carrabba, M, Bernardi, M, Peccatori, J, Moro, M, Biancardi, A, Nizzero, P, Scarpellini, P, Cirillo, D M, Mancini, N, Corti, C, Clementi, M, and Ciceri, F

Abstract

Carbapenemase-producing Klebsiella pneumoniae(KPC-Kp) infections are an emerging cause of death after hematopoietic stem cell transplantation (HSCT). In allogeneic transplants, mortality rate may rise up to 60%. We retrospectively evaluated 540 patients receiving a transplant from an auto- or an allogeneic source between January 2011 and October 2015. After an Institutional increase in the prevalence of KPC-Kp bloodstream infections (BSI) in June 2012, from July 2012, 366 consecutive patients received the following preventive measures: (i) weekly rectal swabs for surveillance; (ii) contact precautions in carriers (iii) early-targeted therapy in neutropenic febrile carriers. Molecular typing identified KPC-Kp clone ST512 as the main clone responsible for colonization, BSI and outbreaks. After the introduction of these preventive measures, the cumulative incidence of KPC-Kp BSI (P=0.01) and septic shocks (P=0.01) at 1 year after HSCT was significantly reduced. KPC-Kp infection-mortality dropped from 62.5% (pre-intervention) to 16.6% (post-intervention). Day 100 transplant-related mortality and KPC-Kp infection-related mortality after allogeneic HSCT were reduced from 22% to 10% (P=0.001) and from 4% to 1% (P=0.04), respectively. None of the pre-HSCT carriers was excluded from transplant. These results suggest that active surveillance, contact precautions and early-targeted therapies, may efficiently control KPC-Kp spread and related mortality even after allogeneic HSCT.

Published
2017
Full Text
View/download PDF

42. Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia.

Author

Greco, R., Mancini, N., Peccatori, J., Cieri, N., Vago, L., Giglio, F., Morelli, M., Ghidoli, N., Carletti, S., Levati, G., Crucitti, L., Sala, E., Lupo Stanghellini, M. T., Lorentino, F., Forcina, A., Pavesi, F., Carrabba, M., Marktel, S., Assanelli, A., and Marcatti, M.

Subjects
ASPERGILLOSIS diagnosis, ACUTE myeloid leukemia diagnosis, HISTOLOGY methodology, DIFFERENTIAL diagnosis, MOLECULAR diagnosis, POLYMERASE chain reaction, TOMOGRAPHY, WHITE people, EARLY diagnosis
Published
2014

43. Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia

Author

Greco R, Mancini N, Peccatori J, Nicoletta Cieri, Vago L, Giglio F, Morelli M, Ghidoli N, Carletti S, Levati G, Crucitti L, Sala E, Mt, Lupo Stanghellini, Lorentino F, Forcina A, Pavesi F, Carrabba M, Marktel S, Assanelli A, Marcatti M, Bernardi M, Corti C, Doglioni C, Scarpellini P, Burioni R, Bonini C, Clementi M, Ciceri F, Greco, R, Mancini, Nicasio, Peccatori, J, Cieri, N, Vago, L, Giglio, F, Morelli, M, Ghidoli, N, Carletti, S, Levati, G, Crucitti, L, Sala, E, Lupo Stanghellini M., T, Lorentino, F, Forcina, A, Pavesi, F, Carrabba, M, Marktel, S, Assanelli, A, Marcatti, M, Bernardi, M, Corti, C, Doglioni, Claudio, Scarpellini, P, Burioni, Roberto, Bonini, MARIA CHIARA, Clementi, Massimo, and Ciceri, Fabio

Subjects
sepsis, voriconazole, aspergillus fumigatus, molecular diagnosis, sepsis, allogeneic transplant, voriconazole, molecular diagnosis, aspergillus fumigatus, Case-Report, allogeneic transplant
Abstract

Diagnosis of invasive fungal infection remains challenging. Here we report a case of early diagnosis of invasive aspergillosis in a neutropenic patient affected by acute myeloid leukaemia, achieved through the detection of Aspergillus fumigatus species-specific ribonucleic acid sequences by a sensitive multiplex real-time polymerase chain reaction-based molecular assay. Thanks to the early diagnosis, targeted therapy was promptly established and the severe fungal infection controlled, allowing the patient to subsequently receive allogeneic hematopoietic stem cell transplantation from a haploidentical donor, her only curative option. Also in this instance, targeted secondary antifungal prophylaxis with voriconazole avoided any other fungal infection afterwards. This report suggests how the implementation of molecular assays in combination with routine diagnostic procedures, can improve microbiological diagnosis in sepsis, particularly in case of fungal infection, difficult to detect with standard microbiological culture methods.

45. HLA disparities on unshared haplotype influence outcomes of unmanipulated haploidentical hematopoietic stem cell transplantation (HaploSCT): A Study from the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation (EBMT)

Author

Lorentino, F., Ciceri, F., Labopin, M., Ruggeri, A., Guelbas, Z., Koc, Y., Arcese, W., Bruno, B., Tischer, J., Lint, M. T., Didier Blaise, Messina, G., Bornhaeuser, M., Fleischhauer, K., Beelen, D. W., Nagler, A., and Mohty, M.

Subjects
Medizin

47. Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching

Author

Antonella Castagna, Paolo Scarpellini, Laura Galli, Jacopo Peccatori, Elisabetta Xue, Lina Uhr, Francesca Lorentino, Marco Ripa, Daniela Clerici, Chiara Oltolini, Massimo Bernardi, Maria Teresa Lupo Stanghellini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Fabio Giglio, Oltolini, C., Greco, R., Galli, L., Clerici, D., Lorentino, F., Xue, E., Lupo Stanghellini, M. T., Giglio, F., Uhr, L., Ripa, M., Scarpellini, P., Bernardi, M., Corti, C., Peccatori, J., Castagna, A., and Ciceri, F.

Subjects
medicine.medical_specialty, Multivariate analysis, Cyclophosphamide, Post transplant cyclophosphamide, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Human leukocyte antigen, Infections, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cystitis, medicine, Humans, Pre-engraftment bloodstream infections, Viral infections, Transplantation, business.industry, Incidence (epidemiology), Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, 030220 oncology & carcinogenesis, Allogeneic hematopoietic stem cell transplantation, Unrelated Donors, Post-transplant cyclophosphamide, business, Early phase, 030215 immunology, medicine.drug
Abstract

Incidence and outcome of infections after allogeneic hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis are largely unknown. Study aims were to estimate the incidence of pre-engraftment bloodstream infections (PE-BSIs) and viral infections (VIs; cytomegalovirus [CMV], adenovirus [ADV], human herpes virus 6 [HHV6], and BK-polyomavirus hemorrhagic-cystitis [BKPyV-HC]), their predictive factors, and infection-related mortality (IRM) after HSCT with PT-Cy. We analyzed 235 patients: 62%, 21%, and 17% received haploidentical (haplo), matched-unrelated donor (MUD), and matched-related donor, respectively. Overall, 72 patients had 77 PE-BSI episodes at a median time of 13 days after HSCT: cumulative incidence function (CIF) at 28 days was 32%, without differences among donor types (P = .988). By multivariate analysis, CIF of PE-BSI was higher in patients with severe neutropenia before HSCT (adjusted hazard ratio [AHR] = 2.90) and in multidrug-resistant Gram-negative bacteria rectal carriers (AHR = 2.68). IRM at 30 days was 5%, without differences by donor type (P = .106). Overall, 208 patients experienced ≥1 VIs (first occurrence among CMV, HHV6, ADV, BKPyV-HC) at a median time of 20 days after HSCT: CIF at 90 days was 91%, significantly higher in MUD and haplo (P = .0089). By multivariate analysis, also acute GVHD grade ≥2 (AHR = 1.32) and host/donor CMV-serology mismatch (positive/positive versus negative/negative: AHR = 2.95, positive/negative versus negative/negative: AHR = 2.41, negative/positive versus negative/negative: AHR = 2.35) affected VIs occurrence. IRM at 180 days was 8%, without differences among donor types (P = .106). In conclusion, study results did not show a significant impact of donor type on PE-BSI incidence; conversely, MUD and haploidentical transplants retained a higher occurrence of VIs in the early phase after HSCT.

Published
2020

48. Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial

Author

Lorenzo Lazzari, Annalisa Ruggeri, Maria Teresa Lupo Stanghellini, Sara Mastaglio, Carlo Messina, Fabio Giglio, Alessandro Lorusso, Tommaso Perini, Simona Piemontese, Magda Marcatti, Francesca Lorentino, Elisabetta Xue, Daniela Clerici, Consuelo Corti, Massimo Bernardi, Andrea Assanelli, Raffaella Greco, Fabio Ciceri, Jacopo Peccatori, Lazzari, L., Ruggeri, A., Lupo Stanghellini, M. T., Mastaglio, S., Messina, C., Giglio, F., Lorusso, A., Perini, T., Piemontese, S., Marcatti, M., Lorentino, F., Xue, E., Clerici, D., Corti, C., Bernardi, M., Assanelli, A., Greco, R., Ciceri, F., and Peccatori, J.

Subjects
Cancer Research, medicine.medical_specialty, Treosulfan, Population, ATLG, Phases of clinical research, Gastroenterology, conditioning regimen, Internal medicine, medicine, Cumulative incidence, Adverse effect, education, RC254-282, Original Research, reduced toxicity, education.field_of_study, business.industry, Hazard ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, allogeneic transplant, Fludarabine, Transplantation, Oncology, business, medicine.drug
Abstract

IntroductionReducing toxicities while preserving efficacy in allogeneic stem cell transplant (allo-HCT) remains a particularly challenging problem. Different strategies to enhance the antitumor activity without increasing early and late adverse toxicities of the conditioning regimens have been investigated.MethodsThe aim of “AlloTreo” prospective phase 2 clinical trial was to evaluate the efficacy and safety of a conditioning regimen based on Treosulfan (42 g/m2) and fludarabine (https://clinicaltrials.gov/ct2/show/NCT00598624). We enrolled 108 patients with hematological diseases who received a first allo-HCT between June 2005 and January 2011, inside the frame of this trial at our center. Median age at allo-HCT was 49 (21–69) years. Disease Risk Index was low in 14 (13%) patients, intermediate in 73 (67.7%), high in 17 (15.7%), and very high in 4 (3.7%). Donors were human leukocyte antigen (HLA)-matched related in 50 cases, 10/10-matched unrelated in 36, and 9/10-mismatched unrelated in 22. Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine-A and methotrexate. Anti-T-lymphocyte globulin (ATLG) was administered in patients receiving unrelated allo-HCT. Stem cell source was mainly peripheral blood stem cells (95%).ResultsConditioning regimen was well tolerated. Full donor chimerism was documented for most patients (88%) at day +30. At 12 years, overall survival (OS) was 41.7% (32.2%–50.9%), progression-free survival (PFS) was 31.7% (23%–40.7%), GvHD-free/relapse-free survival was 20.9% (13.7%–29.1%), cumulative incidence (CI) of relapse was 44.5% (34.9%–53.6%), and transplant-related mortality (TRM) was 22.5% (15.1%–30.9%). CI of acute GvHD grades II–IV was 27.8% (19.7%–36.5%) at 100 days; 12-year CI of chronic GvHD was 40.7% (31.3%–49.9%). Relevant long-term adverse effects were 10 secondary malignancy, 3 fatal cardiovascular events, and 1 late-onset transplant-associated thrombotic microangiopathy. Ten successful pregnancies were reported after allo-HCT. In multivariate analysis, older age (≥60 years) at transplant [hazard ratio (HR), 2.157; p = 0.004] and a high/very high disease risk index (HR, 1.913; p = 0.026) were significantly associated with a lower OS.ConclusionsOverall, our data confirmed the myeloablative potential and safe toxicity profile of full dose Treo (42 g/m2) especially for the younger population.

Published
2021

49. Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older than 65 Years with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A 15-Year Experience

Author

Magda Marcatti, Maria Teresa Lupo Stanghellini, Raffaella Greco, Chiara Secco, Massimo Bernardi, Bernhard Gentner, Lorenzo Lazzari, Elisabetta Xue, Fabio Ciceri, Luca Vago, Francesca Farina, Consuelo Corti, Matteo Carrabba, Sara Mastaglio, Fabio Giglio, Sarah Marktel, Simona Piemontese, Andrea Assanelli, Daniela Clerici, Francesca Lorentino, Jacopo Peccatori, A. Ruggeri, Piemontese, S., Lazzari, L., Ruggeri, A., Marcatti, M., Lupo Stanghellini, M. T., Giglio, F., Greco, R., Lorentino, F., Clerici, D., Assanelli, A., Farina, F., Mastaglio, S., Xue, E., Marktel, S., Vago, L., Gentner, B., Secco, C., Corti, C., Carrabba, M. G., Bernardi, M., Peccatori, J., and Ciceri, F.

Subjects
Oncology, Transplantation, medicine.medical_specialty, Transplantation Conditioning, business.industry, medicine.medical_treatment, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Hematology, Hematopoietic stem cell transplantation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Internal medicine, medicine, Humans, In patient, business
Abstract

Background. Median age of occurrence of acute myeloid leukemias (AML) and myelodisplastc syndromes (MDS) is 65 years and older. Nevertheless, the use of allogeneic stem cell transplant (allo-HCT) has been historically limited to younger population, namely due to excess in non-relapse-mortality (NRM) in olders. Methods. In the present study, we analyzed all consecutive patients aged ≥ 65y diagnosed with AML (71, 81%) or MDS (19, 19%) who received transplants from adult donors at our center from January 2005 to December 2019. Results. Median age was 68.29y (65.02-76.54), 26pts (29%) aged ≥ 70y. Thirty-three (37%) pts received a HLA-matched donor. Conditioning regimen was myeloablative in 46pts (51%). The 3-year overall survival (OS) was 53+/-6%, and disease free survival (DFS) 45+/-6% (Figure 1). Day-100 and 3-year NRM was 17+/-2% and 29+/-2%, respectively. The 3-year CI of relapse was 22+/-2%. Day-100 CI of aGvHD was 21+/-2% for grade II-IV, 14+/-1% for grade III-IV. The 3-year CI of cGvHD was 35+/-3%, extensive 20+/-2%. In multivariate analysis, the Karnofsky Performance Status (KPS) < 90% was associated with lower OS (HR: 2.999, CI: 1.477- 6.691; p=0.002), DFS (HR: 3.155, CI: 1.593 - 6.250; p=0.001) and higher NRM (HR: 2.997, CI: 1.344-6.682; p=0.041). HCT-CI ≥ 3 was also associated with higher NRM (HR: 2.949, CI: 1.166-7.462, p=0.022,). Diagnosis of MDS and receiving a matched donor with PTCy were associated with longer OS (HR: 0.3440, CI: 0.1029-0.915; p=0.033; HR: 0.197, CI: 0.042-0.934; p=0.041).Conclusions. Age alone should not limit transplant eligibility for AML and MDS. KPS and HCT-CI proved to be useful for patient selection among the elderly. The use of HLA-matched donors with PTCy improved OS compared to ATG in our consecutive series.

Published
2021

50. Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients

Author

Massimo Bernardi, Jacopo Peccatori, Edoardo Campodonico, Daniela Clerici, Elisabetta Xue, Fabio Giglio, F. Lorentino, Rosamaria Nitti, Maria Teresa Lupo Stanghellini, Consuelo Corti, Chiara Oltolini, Raffaella Greco, Fabio Ciceri, Francesca Farina, Xue, E., Lorentino, F., Clerici, D., Farina, F., Oltolini, C., Giglio, F., Campodonico, E., Nitti, R., Bernardi, M., Corti, C., Peccatori, J., Ciceri, F., Lupo Stanghellini, M. T., and Greco, R.

Subjects
Oncology, Sirolimus, Transplantation, medicine.medical_specialty, Hematopoietic cell, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, Acetates, Antiviral Agents, Transplant Recipients, Letermovir, Internal medicine, medicine, Quinazolines, Humans, business, medicine.drug
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results